본문 바로가기

Journals

  • Home
  • Cyber Information Center
  • Journals
Journals
Journal Corresponding Author Writer,Title,Journal,Publication;Year;Page:Volume(Impact Factor)
First Author
Economic evaluation of mass screening as a strategy for hepatitis C virus elimination in South Korea Ki, Moran
(Department of Cancer Control and Population Health)

Choi Hwa Young
(Department of Cancer Control and Population Health)
. Economic evaluation of mass screening as a strategy for hepatitis C virus elimination in South Korea. JOURNAL OF INFECTION AND PUBLIC HEALTH. 2025-01-13; 2025; 18(3):102662~. IF 4 (2024)
Factors Associated with Smoking Cessation of Participants in the National Lung Cancer Screening Program in Korea Kim Yeol
(Division of Cancer Screening and Early Detection)


()
. Factors Associated with Smoking Cessation of Participants in the National Lung Cancer Screening Program in Korea. CANCER RESEARCH AND TREATMENT. 2025-01-10; 2025; 57(4):989~999. IF 3.8 (2024)
A proposed framework of strategies to overcome challenges to surgical quality assurance in oncology trials (SQA-Onc.) KIM YOUNG WOO
(Department of Public Health & AI)


()
. A proposed framework of strategies to overcome challenges to surgical quality assurance in oncology trials (SQA-Onc.). EJSO. 2025-01-10; 2025; 51(5):109593~. IF 2.9 (2024)
Feasibility study of patient-specific four-dimensional in vivo tracking system for high-dose-rate brachytherapy: Experimental evaluation
()

Oh Geon
(Center for Proton Therapy)
. Feasibility study of patient-specific four-dimensional in vivo tracking system for high-dose-rate brachytherapy: Experimental evaluation. MEDICAL PHYSICS. 2025-01-09; 2025; 52(4):2533~2550. IF 3.2 (2024)
The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naive primary stage IVB cervical cancer
()

Kim Jun Hwan
(Department of Obstetrics and Gynecology)
. The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naive primary stage IVB cervical cancer. TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY. 2025-01-08; 2025; 64(1):61~67. IF 2.2 (2024)
Epidemiology and survival analysis according to the histologic subtype of pancreatic cancer: a population-based cohort study Jung Kyu-won
(Division of Cancer Registration & Surveillance)

Park Hyeong Min
(Center for Liver and Pancreatobiliary Cancer )
. Epidemiology and survival analysis according to the histologic subtype of pancreatic cancer: a population-based cohort study. ANNALS OF SURGICAL TREATMENT AND RESEARCH. 2025-01-07; 2025; 108(1):20~30. IF 1.6 (2024)
Survival benefits of adjuvant chemotherapy after conversion surgery in patients with advanced pancreatic cancer Woo Sang Myung
(Immuno-oncology Branch)


()
. Survival benefits of adjuvant chemotherapy after conversion surgery in patients with advanced pancreatic cancer. FRONTIERS IN ONCOLOGY. 2025-01-07; 2025; 14:1510016~. IF 3.3 (2024)
The association between residing in regions with population decline and receiving management education or treatment in patients with hypertension
()

Kim Woo Rim
(Hospice Policy & Planning Team)
. The association between residing in regions with population decline and receiving management education or treatment in patients with hypertension. JOURNAL OF PUBLIC HEALTH. 2025-01-07; 2025; 47(3):e329~e343. IF 3.1 (2024)
Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline)
()

Choi Won Young
(Cancer Molecular Biology Branch)
. Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline). JOURNAL OF GASTRIC CANCER. 2025-01-06; 2025; 25(1):5~114. IF 3.8 (2024)
Cross-sectional study of lung cancer patients as a potential high-risk factor for abdominal aortic aneurysm
()

Gwon Hye Ran
(Branch of Pulmonology)
. Cross-sectional study of lung cancer patients as a potential high-risk factor for abdominal aortic aneurysm. PLOS ONE. 2025-01-06; 2025; 20(1):e0315898~. IF 2.6 (2024)